
    
      PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study.
      Patients are stratified according to center and etiology of disease.

      Patients receive conventional oral therapy plus a continuous subcutaneous infusion of either
      UT-15 or placebo for 12 weeks.

      After completing 12 weeks of treatment, patients may continue therapy with open label UT-15.
      Patients who received placebo cross over to receive UT-15.

      Completion date provided represents the completion date of the grant per OOPD records
    
  